Benzinga | Dec 10, 2021 05:28AM EST

JP Morgan Initiates Coverage On Cytokinetics with Overweight Rating, Announces Price Target of $58

JP Morgan analyst Anupam Rama initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Overweight rating and announces Price Target of $58.